GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Net Income Including Noncontrolling Interests

Cellectis (XPAR:ALCLS) Net Income Including Noncontrolling Interests : €-55.36 Mil (TTM As of Mar. 2025)


View and export this data going back to 2007. Start your Free Trial

What is Cellectis Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Cellectis's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was €-16.77 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was €-55.36 Mil.

Cellectis Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Cellectis's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Net Income Including Noncontrolling Interests Chart

Cellectis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -80.13 -110.72 -107.65 -99.44 -35.11

Cellectis Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.19 -23.48 -20.77 5.66 -16.77

Cellectis Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-55.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Cellectis's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XPAR:OSE XPAR:NANO XPAR:IPH XPAR:ALSEN XPAR:GNFT XPAR:TNG XPAR:DBV XPAR:MAAT XPAR:ADOC XPAR:ALGAE VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
CMVLF:USA CLLS:USA 0WA2:UK ZVA:Germany
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Website
https://www.cellectis.com
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines